Aktis Oncology Earnings Call Transcripts
Fiscal Year 2026
-
The company is advancing miniprotein radioconjugate therapies targeting Nectin-4 and B7-H3, supported by a robust discovery platform and strong financial position. Key clinical updates are expected in 2027, with ongoing collaborations and manufacturing investments to accelerate development and patient access.
-
AKY-2519, a B7-H3-targeted radioconjugate, has entered phase I-B trials for mCRPC, with a parallel basket trial in other solid tumors planned for late 2026. Imaging and dosimetry data will be presented at ASCO, and preliminary clinical data are expected in 2027.
-
The company is advancing a novel radiopharmaceutical platform with lead programs targeting Nectin-4 and B7-H3, both showing promising early clinical and imaging data. Robust supply chain, strong financials, and strategic partnerships position it for broad impact and sustained growth.
-
Radiopharmaceuticals are poised for major growth, with new miniprotein binder technology enabling first-in-class therapies targeting Nectin-4 and B7-H3. Robust supply chain, strategic partnerships, and a strong team support rapid clinical advancement and broad market potential.